
==== Front
Eur Heart J Case Rep
Eur Heart J Case Rep
ehjcr
European Heart Journal. Case Reports
2514-2119
Oxford University Press UK

10.1093/ehjcr/ytae440
ytae440
Case Report
Inherited Cardiac Conditions/Cardiomyopathies
AcademicSubjects/MED00200
Eurheartj/12
Low foetal heart rate, a potentially ominous finding: case report
https://orcid.org/0009-0000-0318-734X
Afana Andreea Sorina Expert Center for Genetic Cardiovascular Diseases, Emergency Institute for Cardiovascular Diseases, 258 Fundeni Street, Bucharest 022328, Romania

https://orcid.org/0000-0002-3824-1489
Filip Cristina Neonatal Intensive Care Unit, University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blv., Bucharest 050474, Romania

https://orcid.org/0000-0002-9745-9891
Cimpoca Brindusa Department of Obstetrics and Gynecology, University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blv., Bucharest 050474, Romania

https://orcid.org/0000-0002-0804-6690
Dumitrascu-Biris Ioana Fetal Medicine Department, Filantropia Clinical Hospital, 11-13 Ion Mihalache Blv., Bucharest 011171, Romania

https://orcid.org/0000-0002-3438-2612
Jurcut Ruxandra Department of Cardiothoracic Pathology, University of Medicine and Pharmacy Carol Davila, 8 Eroii Sanitari Blv., Bucharest 050474, Romania

Sohns Christian Handling Editor
Agarwal Megha Editor
Corresponding author. Tel: +40784022421, Email: andreea.afana@gmail.com
Conflict of interest: None declared.

9 2024
01 9 2024
01 9 2024
8 9 ytae44014 8 2024
15 8 2024
19 8 2024
01 9 2024
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
2024
https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Congenital long QT syndrome (LQTS) type 1 is characterized by abnormally prolonged ventricular repolarization caused by inherited defects in cardiac potassium channels. Patients are predisposed to ventricular arrhythmias and even sudden cardiac death. In some cases, foetal sinus bradycardia is the only sign, making prenatal diagnosis challenging. Physicians should be aware of this subtle presentation of LQTS. Early diagnosis and proactive treatment are crucial for preventing unexpected cardiac events.

Case summary

A healthy and asymptomatic 25-year-old pregnant woman was referred to our institute for cardiac evaluation after persistent foetal sinus bradycardia was detected during repeated ultrasounds, despite the absence of any foetal morphological or functional cardiac anomalies. After a thorough assessment, the mother was diagnosed with LQTS type 1, as confirmed by molecular genetic testing. Appropriate management, including maternal medication and increased surveillance, was initiated. The infant was delivered safely, and his electrocardiogram revealed a significantly prolonged QTc interval. Genetic testing confirmed the maternally inherited variant in KCNQ1 gene, and beta-blocker therapy was started. No arrhythmic events were noted.

Discussion

Detection and careful stratification of foetal heart rate (FHR) is crucial in every pregnancy. Foetal bradycardia can be caused by both maternal and foetal factors. Persistent low FHR should raise a high suspicion for LQTS. The condition may also present with atrioventricular blocks, torsades de pointes, or sudden intrauterine foetal demise. Accurate and early diagnosis of LQTS is essential for implementing appropriate management strategies, which include vigilant monitoring, effective medical treatment, careful planning of delivery, and post-natal care.

Congenital long QT syndrome
Long QT syndrome type 1
Foetal bradycardia
Potassium channels
Channelopathy
Case report
==== Body
pmcLearning points

In the majority of long QT syndrome type 1 patients, foetal sinus bradycardia, defined as foetal heart rate < 110 b.p.m. (or <3rd percentile for gestational age), is the only foetal arrhythmia detected in utero on routine prenatal ultrasound.

Transplacental therapy generally consists of beta-blockers, most often in the form of propranolol because of its efficient transplacental passage.

Introduction

In clinical practice, foetal echocardiography and cardiotocography have been the cornerstones for assessing foetal well-being and identifying foetal arrhythmias.

Foetal bradycardia is defined as a foetal heart rate (FHR) of less than 110 b.p.m. by the American College of Obstetrics and Gynecology1 and the International Society of Ultrasound in Obstetrics and Gynecology.2 Additionally, specific percentiles for gestational age are used in FHR monitoring, as rates below the 3rd percentile can accurately identify conduction disease.3 Foetal bradycardia can be attributed to various aetiologies, including maternal hypothyroidism, effects from maternal medications (such as beta-blockers and antithyroid agents), maternal antibody-induced sinus node dysfunction (anti-Ro/anti-La antibodies), congenital complete heart block, long QT syndrome (LQTS), and other inherited channelopathies. The differential diagnosis is important because it allows for the selection of the most effective therapeutic strategies.

Long QT syndrome is responsible for 15–17% of cases of foetal bradycardia with heart rates below 110 b.p.m. in foetuses with a normally structured heart.4

Diagnosing LQTS in utero is especially difficult and frequently delayed, as routine ultrasound findings are usually subtle, often revealing only incidental cases of sustained foetal bradycardia. Diagnosing LQTS before birth is crucial, as it is responsible for a significant number of late-term foetal losses and cases of sudden infant death.5

Summary figure

An apparently healthy pregnant woman was found to have a foetus with persistent sinus bradycardia. Comprehensive evaluation revealed LQTS type 1, leading to increased surveillance and beta-blocker therapy. Post-natal evaluation confirmed that the infant had a prolonged QTc interval, with genetic testing identifying a maternally inherited KCNQ1 variant. Beta-blocker therapy was initiated for the infant.

Case presentation

A healthy 25-year-old woman, 32 weeks pregnant with good prenatal care, was referred to adult cardiology for evaluation after her foetus was found on routine foetal ultrasounds to have bradycardia. Her obstetric, personal, and family histories were otherwise unremarkable. This was her second pregnancy, following an uncomplicated first.

Foetal bradycardia was initially detected in the first trimester. Her primary physician continued to closely monitor the foetal heart rate through serial ultrasounds. She was referred to a foetal medicine specialist for a more comprehensive evaluation, where the foetal echocardiogram revealed normal chamber dimensions and good ventricular function. On follow-up, the most recent examination at 35-week gestation showed no morphological or functional cardiac anomalies, but the sinus bradycardia persisted, with FHR ranging from 108 to 119 b.p.m. (Figure 1).

Figure 1 Foetal echocardiography at 35-week gestation showing a ventricular heart rate of 108 b.p.m. (A) with normal atrioventricular intervals (B).

The mother was not undergoing any treatment with bradycardic effects. As part of an initial evaluation, laboratory testing for anti-Ro/La antibodies was performed, revealing negative status. Her thyroid status and serum electrolyte levels were normal.

The maternal echocardiogram was unremarkable, but her electrocardiogram (ECG) demonstrated a slightly prolonged QT interval (corrected QT interval 482 ms based on Bazett’s formula) (Figure 2). The paternal ECG was normal.

Figure 2 Electrocardiogram of the mother showing a slightly prolonged QTc interval of 482 ms.

There was no maternal history or symptoms of arrhythmias. Genetic testing for LQTS, using a dedicated panel of 18 genes (Blueprint Genetics, Finland), was offered to the pregnant woman. The results revealed a pathogenic heterozygous variant (c.949G>A, p.Asp317Asn, NM_000218.3) in the KCNQ1 gene, which encodes the alpha subunit of a voltage-gated K+ channel and is associated with autosomal dominant LQTS type 1. Despite being asymptomatic, the pregnant woman began treatment with beta-blockers (propranolol).

A caesarean delivery was planned owing to concerns about potentially inadequate cardiac monitoring during vaginal delivery. The infant was delivered at 37-week gestation with an APGAR score of 9/9 and remained haemodynamically stable the entire time. Post-natal echocardiogram showed bradycardic rhythm in the presence of otherwise normal findings. Electrocardiography confirmed the diagnosis of significant QT prolongation (corrected QT interval 510–561 ms) (Figure 3).

Figure 3 Electrocardiogram of the neonate showing sinus bradycardia with prolonged QT interval of 516 ms.

The neonate was started on propranolol to sustain the reduction in QT interval, with the dose gradually increased to a daily dosage of 2 mg/kg/day, under strict ECG monitoring due to the low heart rate. Post-natal genetic testing confirmed the final diagnosis of a pathogenic, maternally inherited variant in KCNQ1 (c.949G>A, p.Asp317Asn). The infant was discharged home and continues to do well, with no arrhythmic events. Over the 10-month follow-up, the infant displayed normal growth and neurodevelopment and remained asymptomatic, but continued to have a slightly prolonged QTc interval (480–490 ms) despite being on propranolol prophylaxis. Genetic testing for LQTS was also recommended for the firstborn child, and the results were negative. Parents were educated about medications that should be avoided due to their potential to prolong QT intervals, and they were advised to treat promptly any intestinal disorders that can lead to low electrolytes level, to avoid intense physical activity and extreme emotional stress in the future.

Discussion

Congenital LQTS is a group of inherited channelopathies, primarily involving three major autosomal dominant subtypes (types 1, 2, and 3), LQTS type 1 being the most common.6,7 These conditions are linked to impaired cardiac repolarization and an increased risk of life-threatening ventricular arrhythmias at any age. Foetuses with LQTS type 1 have a significantly shorter QTc interval compared with the other two types,8 and they generally have a more favourable prognosis.9

The prenatal diagnosis is particularly challenging and requires the recognition of specific rhythm abnormalities unique to the foetus. In the majority of LQTS type 1 patients, foetal sinus bradycardia is often the only foetal arrhythmia detected in utero on routine prenatal ultrasound.3 The post-natal diagnosis of LQTS is typically clear-cut, indicated by a prolonged QT interval revealed by an ECG, a positive family history, or characteristic LQTS arrhythmias. This diagnosis can be confirmed through genetic testing, as it was in the case of this child.

Ideally, LQTS should be diagnosed before birth to ensure optimal management for both the mother and the child. During foetal life, the most effective treatment is transplacental therapy, which generally consists of beta-blockers, most commonly in the form of propranolol, due to its efficient passage across the placenta.10 The treatment is typically tailored according to the dynamically changing status of both the mother and the foetus. Awareness of foetal LQTS will prompt the withholding or reduction of QT-prolonging maternal medications commonly used in obstetrics, such as oxytocin or ondansetron. An implantable cardioverter-defibrillator (ICD) is recommended post-natal for patients who do not respond to beta-blocker therapy and are at high risk for sudden cardiac death.11 Given that the infant responded well to the medical therapy and did not experience any arrhythmic events, the potential benefits of an ICD did not justify the associated risks. Recognition of maternal LQTS is equally important, as the risk of cardiac events increases during the postpartum period.12 Risk stratification for the expectant mother is a crucial step, as outlined in the 2018 ESC guidelines for managing cardiovascular diseases during pregnancy.13 This includes implementing varying levels of surveillance in specialized centres, choosing the appropriate method and location for delivery, and determining whether to start or stop specific medications.14 Such patients need close multidisciplinary follow-up for well-being and complications, delivery in a tertiary facility where comprehensive cardiac care is available for both the mother and the newborn.15

Patient’s perspective

A patient coming from a family without any known cardiac diseases should receive adequate genetic counselling, and predictive family screening should be offered to all first-degree relatives. In LQTS patients, education should include avoiding drugs and situations which could further prolong QT interval. Our young mother and her spouse showed a good understanding of all medical explanations.

Acknowledgements

We thank the patient and his family for allowing us to present this case. We would also like to thank Dr Maria Ciocarlan, Dr Diana Jecan Toader, Dr Alina Veduta, Dr Mihaela Bizubac, and Dr Catalin Cirstoveanu for the patient care and their helpful discussions.

Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with the COPE guidelines.

Funding: None declared.

Lead author biography

Dr Afana Andreea Sorina studied medicine at the University of Medicine and Pharmacy of Craiova, Romania. She is currently a cardiology resident specializing in multimodal cardiovascular imaging at the MIRACL.ai Laboratory, Multimodality Imaging for Research and Analysis Core Laboratory, and Artificial Intelligence at the University Hospital of Lariboisière (AP-HP) in Paris, France. Her research focuses on genetic cardiac disorders, and she undertook a 1.5-year training at the Expert Center for Rare Genetic Cardiovascular Diseases, Emergency Institute for Cardiovascular Diseases Prof. Dr C.C. Iliescu in Bucharest, Romania.

Data availability

The data underlying this article are available in the article and in its online supplementary material.
==== Refs
References

1 American College of Obstetricians and Gynecologists . Practice bulletin no. 116: management of intrapartum fetal heart rate tracings. Obstet Gynecol  2010;116 :1232–1240.20966730
2 Carvalho  JS, Axt-Fliedner  R, Chaoui  R, Copel  JA, Cuneo  BF, Goff  D, et al  ISUOG practice guidelines (updated): fetal cardiac screening. Ultrasound Obstet Gynecol  2023;61 :788–803.37267096
3 Mitchell  JL, Cuneo  BF, Etheridge  SP, Horigome  H, Weng  HY, Benson  DW. Fetal heart rate predictors of long QT syndrome. Circulation  2012;126 :2688–2695.23124029
4 Ishikawa  S, Yamada  T, Kuwata  T, Morikawa  M, Yamada  T, Matsubara  S, et al  Fetal presentation of long QT syndrome—evaluation of prenatal risk factors: a systematic review. Fetal Diagn Ther  2013;33 :1–7.22776830
5 Chivers  S, Ovadia  C, Regan  W, Zidere  V, Vigneswaran  T, Sharland  G, et al  Systematic review of long QT syndrome identified during fetal life. Heart Rhythm  2023;20 :596–606.36566891
6 Shimizu  W, Horie  M. Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels. Circ Res  2011;109 :97–109.21700951
7 Napolitano  C, Priori  SG, Schwartz  PJ, Bloise  R, Ronchetti  E, Nastoli  J, et al  Genetic testing in the long QT syndrome. JAMA  2005;294 :2975.16414944
8 Strand  S, Strasburger  JF, Cuneo  BF, Wakai  RT. Complex and novel arrhythmias precede stillbirth in fetuses with de novo long QT syndrome. Circ Arrhythm Electrophysiol  2020;13 :e008082.32421437
9 Moore  JP, Gallotti  RG, Shannon  KM, Bos  JM, Sadeghi  E, Strasburger  JF, et al  Genotype predicts outcomes in fetuses and neonates with severe congenital long QT syndrome. JACC Clin Electrophysiol  2020;6 :1561–1570.33213816
10 Cuneo  BF, Etheridge  SP, Horigome  H, Sallee  D, Moon-Grady  A, Weng  HY, et al  Arrhythmia phenotype during fetal life suggests long-QT syndrome genotype: risk stratification of perinatal long-QT syndrome. Circ Arrhythm Electrophysiol  2013;6 :946–951.23995044
11 Horner  JM, Kinoshita  M, Webster  TL, Haglund  CM, Friedman  PA, Ackerman  MJ. Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience. Heart Rhythm  2010;7 :1616–1622.20816872
12 Seth  R, Moss  AJ, McNitt  S, Zareba  W, Andrews  ML, Qi  M, et al  Long QT syndrome and pregnancy. J Am Coll Cardiol  2007;49 :1092–1098.17349890
13 Regitz-Zagrosek  V, Roos-Hesselink  JW, Bauersachs  J, Blomström-Lundqvist  C, Cífková  R, De Bonis  M, et al  2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J  2018;39 :3165–3241.30165544
14 Marcinkeviciene  A, Rinkuniene  D, Puodziukynas  A. Long QT syndrome management during and after pregnancy. Medicina (B Aires)  2022;58 :1694.
15 Roston  TM, van der Werf  C, Cheung  CC, Grewal  J, Davies  B, Wilde  AAM, et al  Caring for the pregnant woman with an inherited arrhythmia syndrome. Heart Rhythm  2020;17 :341–348.31400520
